Pardes Biosciences (FS Development II) ^{Priced, Nasdaq: PRDS}

We are a newly organized blank check company. While we may pursue an initial business combination target in any business industry or geographic region, we intend to capitalize on our management team’s background and experience to identify promising opportunities in the biotechnology and life science infrastructure sector. We were co-founded by Foresite Capital Management, LLC, an investment firm with approximately $3.5 billion in assets under management as of December 31, 2020 (“Foresite Capital”) and Jim Tananbaum, our President, Chief Executive Officer and a director. Foresite Capital, which is a member of our sponsor and is our affiliate, was established in 2011 by Jim Tananbaum and has been focused on therapeutic companies within the biotechnology sector. As Foresite Capital’s affiliate, we will benefit from our access to Foresite Capital’s infrastructure, personnel, network and relationships. Foresite Capital’s investment team is in regular contact with entrepreneurs, key opinion leaders, management teams, and contacts in the venture capital and investment banking communities to source new deals. Our robust screening and due diligence process includes numerous meetings or calls with management and leverages Foresite’s expansive network of key opinion leaders, healthcare company executives, entrepreneurs and leading academics.